The estimated Net Worth of Patrick A Barry is at least 2.31 百万$ dollars as of 29 March 2022. Mr. Barry owns over 59,298 units of Endo International plc stock worth over 51,113$ and over the last 7 years he sold ENDP stock worth over 0$. In addition, he makes 2,257,800$ as Executive Vice President and Chief Commercial Officer、 U.S. Branded Business at Endo International plc.
Sign up
Mr. Barry ENDP stock SEC Form 4 insiders trading
Patrick has made over 3 trades of the Endo International plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 59,298 units of ENDP stock worth 17,351$ on 29 March 2022.
The largest trade he's ever made was exercising 59,298 units of Endo International plc stock on 29 March 2022 worth over 17,351$. On average, Patrick trades about 8,232 units every 45 days since 2018. As of 29 March 2022 he still owns at least 174,686 units of Endo International plc stock.
You can see the complete history of Mr. Barry stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Patrick Barry biography
Patrick Barry serves as Executive Vice President and Chief Commercial Officer, U.S. Branded Business of the Company. In this role, he has responsibility for all commercial activities for U.S. Branded Pharmaceuticals, including strategy, new product planning, marketing, sales as well as managed care and patient access responsibilities. Mr. Barry joined Endo in December 2016 as Senior Vice President, U.S. Branded Pharmaceuticals. Prior to joining Endo, Mr. Barry worked at Sanofi S.A. from 1992 until December 2016, holding roles of increasing responsibility in areas such as Sales Leadership, Commercial Operations, Marketing, Launch Planning and Training and Leadership Development. Most recently, he served at Sanofi S.A. as its General Manager and Head of North America General Medicines starting in September 2015 and as Vice President and Head of U.S. Specialty from April 2014 until August 2015. During this time, Mr. Barry oversaw three complex and diverse businesses with responsibility for leading sales and marketing activities for branded and generic products across the U.S. and Canada. He has a diverse therapeutic experience including aesthetics and dermatology, oncology, urology, orthopedics and medical device and surgical experience. He has an M.B.A. from Cornell University, Johnson School of Management and a B.A. in Public Relations and Marketing from McKendree University.
What is the salary of Patrick Barry?
As the Executive Vice President and Chief Commercial Officer、 U.S. Branded Business of Endo International plc, the total compensation of Patrick Barry at Endo International plc is 2,257,800$. There are 5 executives at Endo International plc getting paid more, with Paul Campanelli having the highest compensation of 13,118,300$.
How old is Patrick Barry?
Patrick Barry is 52, he's been the Executive Vice President and Chief Commercial Officer、 U.S. Branded Business of Endo International plc since 2018. There are 9 older and 7 younger executives at Endo International plc. The oldest executive at Endo International plc is Michael Hyatt, 74, who is the Independent Director.
What's Patrick Barry's mailing address?
Patrick's mailing address filed with the SEC is C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN, L2, .
Insiders trading at Endo International plc
Over the last 11 years, insiders at Endo International plc have traded over 3,455,441$ worth of Endo International plc stock and bought 152,347 units worth 3,901,804$ . The most active insiders traders include Silva Rajiv De、Paul Campanelli、Shane Cooke. On average, Endo International plc executives and independent directors trade stock every 36 days with the average trade being worth of 12,163$. The most recent stock trade was executed by Patrick A Barry on 29 March 2022, trading 59,298 units of ENDP stock currently worth 17,351$.
What does Endo International plc do?
Endo is a specialty pharmaceutical company committed to helping everyone it serves live their best life through the delivery of quality, life-enhancing therapies. Its decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, it boldly transforms insights into treatments benefiting those who need them, when they need them.
What does Endo International plc's logo look like?
Complete history of Mr. Barry stock trades at Endo International plc
Endo International plc executives and stock owners
Endo International plc executives and other stock owners filed with the SEC include:
-
Paul Campanelli,
Chairman of the Board -
Terrance Coughlin,
Chief Operating Officer, Executive Vice President -
Blaise Coleman,
Pres, CEO & Director -
Blaise Coleman,
President, Chief Executive Officer, Director -
Matthew Maletta,
Executive Vice President, Chief Legal Officer -
Patrick Barry,
Executive Vice President and Chief Commercial Officer, U.S. Branded Business -
Patrick A. Barry,
Exec. VP & Pres of Global Commercial Operations -
Mark T. Bradley,
Exec. VP & CFO -
Roger Kimmel,
Senior Independent Director -
Shane Cooke,
Independent Director -
William Montague,
Independent Director -
Nancy Hutson,
Independent Director -
Michael Hyatt,
Independent Director -
M. Christine Smith,
Independent Director -
Mark Barberio,
Independent Director -
Jack Boyle,
Senior Vice President - Financial Planning & Analysis, Chief Accounting Officer, Controller -
Rahul Garella,
Executive Vice President, International Pharmaceuticals -
Domenico Ciarico,
Executive Vice President and Chief Commercial Officer, Sterile and Generics -
Joseph A. Barbarite,
Exec. VP of Global Quality and Compliance -
Tracy Basso,
Chief HR Officer -
Susan Williamson,
Sr. VP & Chief Compliance Officer -
Laure E. Park,
Sr. VP of Investor Relations & Corp. Affairs -
Ruth Thorpe,
Sr. VP of Information Technology & Chief Information Officer -
Robert Polke,
Exec. VP & Global Head of Operations -
Arthur J Higgins,
Director -
Douglas S Ingram,
Director -
Hemanth Jacob Varghese,
Pres. International Pharma -
Suketu Upadhyay,
EVP, Chief Financial Officer -
Antonio R Pera,
President, Par Pharmaceutical -
Joseph Ciaffoni,
President, U.S. Branded Pharma -
Carrie Ann Nichol,
SVP, Controller & CAO -
Mark T. Bradley,
EVP, Chief Financial Officer -
Frank B. Raciti,
VP, Controller and CAO -
Daniel Rudio,
Vice President, Controller -
Sharad Mansukani,
Director -
William Spengler,
Director -
Silva Rajiv De,
President & CEO -
John Delucca,
Director -
Brian Lortie,
President Branded Pharma -
Susan Hall,
EVP, CSO, Global Head of R&D -
Caroline B Manogue,
Exec. V.P., CLO & Secy -
Camille Farhat,
President, AMS, Inc. -
Ivan P. Gergel,
EVP, R&D and CSO -
Donald W De Golyer,
Chief Operating Officer,Pharma -
Mary Christine Smith,
Director -
George Apostol,
EVP, Global R&D -
Jennifer M Chao,
Director -
James Patrick Tursi,
Executive VP, Global R&D